- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04991974
Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine (OUTLAST-B)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study, entitled Opioid Use Disorder Treatment Linkage at Sexual Health Clinics using Buprenorphine (OUTLAST-B), will examine opioid use disorder (OUD) treatment linkage strategies for people receiving sexual health services from public clinics and health departments. This three-arm, parallel randomized clinical trial (RCT) will compare Usual Care (UC), vs. referral via Patient Navigation (PN), vs. Patient Navigation with buprenorphine initiation (PN+BUP).
The UC Arm will include standard services at the sexual health clinic / city health department.
The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment.
The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community.
Research assessments consisting of a structured interview battery and biomarkers for drug use and sexually transmitted infections will be conducted at baseline, 3-, and 6-month follow-up. Selected outcomes will be examined through 12-months via health record linkage methods. The study will examine participant outcomes in the domains of: (1) OUD treatment entry and retention, (2) Opioid use and related problems (including fatal and non-fatal overdose), and (3) HIV/STD-related outcomes.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Friends Research Institute
-
Baltimore, Maryland, United States, 21202
- Baltimore City Health Department Sexual Health Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older
- Opioid use in the past 30 days
- DSM-5 diagnostic criteria for OUD with physiological dependence
- Willing to try buprenorphine treatment.
Exclusion Criteria:
- current enrollment in OUD treatment with buprenorphine, methadone, or extended-release naltrexone
- clinical contraindication with buprenorphine (e.g., allergy to buprenorphine or naloxone, chronic pain management with opioid agonists)
- regular use of illicit long-acting opioid agonists (e.g., methadone; due to potential challenges with dose induction)
- heavy alcohol use that, in the judgement of the prescribing provider, raises a safety concern that precludes eligibility for buprenorphine induction
- high dose or intravenous benzodiazepine misuse
- pregnancy (due to special needs; will be treated outside of the study)
- unstable medical or psychiatric illness (e.g., psychosis or active suicidal ideation)
- inability to provide informed consent (e.g., failure to pass consent quiz)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care (UC)
The UC Arm will include standard services from the sexual health clinic / city health department [at the time of the study, no standardized intervention for opioid use disorder treatment linkage].
|
|
Active Comparator: Patient Navigation (PN)
The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment.
|
A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
|
Experimental: Patient Navigation + Buprenorphine Initiation (PN+BUP)
The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community.
The standard buprenorphine bridge prescription will be for buprenorphine/naloxone film: 8/2mg, up to 16mg per day, 7 day supply.
|
A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study). Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OUD treatment entry (number [%] of participants who enter OUD treatment)
Time Frame: 1 month
|
The primary outcome for the trial is OUD treatment entry by 1 month post-enrollment, defined as admission to a buprenorphine provider (either office-based care or a specialty OUD program), or other licensed OUD treatment program (e.g., methadone, medical detox followed by behavioral treatment).
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OUD treatment retention
Time Frame: 6 months
|
Treatment retention will be examined as a secondary outcome and will be determined by self-report, with confirmation of admission/discharge dates through provider records if available.
|
6 months
|
Opioid use (self-report)
Time Frame: 6 months
|
Self-reported days of opioid use in the past 30 days
|
6 months
|
Opioid use (urine test)
Time Frame: 6 months
|
Opioid urine drug test
|
6 months
|
Cocaine use (self-report)
Time Frame: 6 months
|
Self-reported days of cocaine use in the past 30 days
|
6 months
|
Cocaine use (urine test)
Time Frame: 6 months
|
Cocaine urine drug test
|
6 months
|
OUD diagnostic criteria
Time Frame: 6 months
|
Opioid use disorder diagnostic criteria will be assessed using items from the OUD criteria checklist derived from the modified World Mental Health-Composite International Diagnostic Interview (WMH-CIDI) items that map to the diagnostic criteria.
The time frame of the criteria will be modified to past 30 days to capture acute changes.
|
6 months
|
Opioid overdose
Time Frame: 6 months
|
Participants will be asked at follow-up about non-fatal opioid overdose experiences.
We will obtain medical examiner reports to confirm fatal overdoses.
|
6 months
|
New Diagnoses of HIV/STIs
Time Frame: 6 months
|
New diagnoses of HIV and sexually transmitted infections will be determined via self-report and health department records.
|
6 months
|
Adherence to recommended HIV/STI treatment
Time Frame: 6 months
|
Participants will be asked at follow-up whether they took as directed their specific HIV/STI medications, including (if applicable) any extended antibiotics for bacterial STDs, antiretroviral therapy for HIV+ participants, and PrEP to safeguard against acquiring HIV.
|
6 months
|
Sex Risk Behaviors
Time Frame: 6 months
|
Risky sex behaviors will be gauged by self-report, and include past 90 day frequency of unprotected sex and number of sex partners.
|
6 months
|
Drug Risk Behaviors
Time Frame: 6 months
|
Risky drug injection practices in the past 90-days, gauged by self-report
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jan Gryczynski, Friends Research Institute, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Narcotic-Related Disorders
- Substance-Related Disorders
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
- Naloxone
- Buprenorphine, Naloxone Drug Combination
Other Study ID Numbers
- R01DA045724 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
- Application to Friends Research Institute.
- Approval of the application and secondary analysis protocol by Friends Research Institute.
- Execution of a data use agreement between the requesting party and Friends Research Institute.
- IRB-approval of the proposed secondary research protocol.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
Clinical Trials on Patient Navigation
-
University of Colorado, DenverDenver Health and Hospital Authority; Rocky Mountain Human Services; El Grupo...Completed
-
Kaiser PermanenteNational Cancer Institute (NCI); Sea Mar Community Health CentersCompletedColorectal CancerUnited States
-
University of Texas Southwestern Medical CenterCancer Prevention Research Institute of TexasCompletedPrevention Harmful Effects | Compliance Behavior | Non-Small Cell Lung CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRalph Lauren Center for Cancer Care and Prevention; North General Hospital,...CompletedBreast CancerUnited States
-
Northwestern UniversityNortheastern Illinois UniversityRecruiting
-
Renato Cagnacci NetoM.D. Anderson Cancer Center; Eduardo Mondlane University; Hospital Central de... and other collaboratorsNot yet recruitingA Prospective Cohort With Patient Navigation as an Intervention for Breast Cancer Patients (NAVIMOZ)Breast Neoplasm Malignant Primary
-
Horizon Health NetworkRecruitingFrailty | Aging | FractureCanada
-
Medical University of South CarolinaCompletedCancer of Head and NeckUnited States
-
Massachusetts General HospitalCompleted
-
Case Western Reserve UniversityNational Institute of Nursing Research (NINR)CompletedChronic Disease | HIVUnited States